FDA Recommends Multiregional Trial After Rejecting Summit’s Cancer Drug Application
Key Facts
The U.S. Food and Drug Administration recommended that Summit Therapeutics submit results from a new multiregional clinical trial before supporting an application for approval of ivonescimab, after concluding that the evidence submitted did not establish sufficient clinical benefit. In its letter, the agency said the trial should be adequately controlled to show a statistically significant and clinically meaningful improvement in overall survival, progression-free survival or another endpoint measuring clinical benefit. The FDA linked its recommendation to concerns about whether the study results could be generalized to U.S. patients, as well as to the overall survival results and response rate. It also recommended that Summit discuss the trial design and endpoints with the agency before starting the trial. That makes the application pathway contingent on generating new clinical evidence, while the letter sets no timeline for completing the trial or submitting its results.
The FDA said the generalizability of the primary endpoint, progression-free survival, to the U.S. population had not been established because 93% of events for that endpoint in the HARMONi analysis occurred among patients enrolled in China. Those events included 257 of the 275 total. That proportion raises the question of how applicable the primary result is to the population targeted by the U.S. approval application. The agency described the improvement in median progression-free survival as modest. The final overall survival analysis showed no statistically significant improvement, and the overall response rate showed no meaningful difference. The FDA therefore did not view the progression endpoint alone as offsetting the lack of definitive, statistically significant evidence of longer survival or improved response.
The agency added that the company’s analyses of progression-free survival and overall survival after the study ended, based on longer follow-up, remained exploratory. It also said differences in data cutoff dates across regions further limited the later overall survival analyses. This assessment distinguishes the results of the study’s prespecified final analysis from signals that emerged in subsequent follow-up, as the FDA did not consider the latter conclusive evidence supporting the application. Summit had reported in a later analysis an overall survival hazard ratio of 0.76 in the Western patient group, saying the result was consistent with the full and Asian groups. The company said those results had been made available to the agency. But the FDA letter described the later follow-up analyses as exploratory, while recommending a new trial that would show clinical benefit that could be assessed.
The FDA had set November 14, 2026, as the target date for a decision on the application, according to Summit’s filing with the U.S. Securities and Exchange Commission. The company said in the filing that the agency had indicated that demonstrating a statistically significant overall survival benefit was necessary to support approval in this setting. That is consistent with the rejection letter’s focus on the absence of a statistically significant improvement in final overall survival, alongside limits on generalizing the progression-free survival result. In a separate third-quarter filing, Summit said the number of progression-free survival events needed for the primary analysis in the squamous cell cohort of the HARMONi-3 trial was expected to be reached during the fourth quarter of 2026. It added that an interim overall survival analysis, independent of the progression-free survival analysis, was planned for the first half of 2027.
In premarket trading, Summit shares closed at $14.15 on November 13 and $11.82 on November 16, according to EL7 daily data; the two closing prices were from sessions before the news session. Investing.com reported that the stock fell 17.5% in premarket trading to $11.68 after the FDA letter was issued, in a report dated November 16. It also said Jefferies considered the rejection an expected scenario for investors. Barclays cut its price target on the stock to $18 from $20, while maintaining an “equal weight” rating. Verified data on prices for the Tuesday, November 17 session are not available here, so these figures are not attributed to that session.